Skip to content

Harrow HROW Long Term Notes Payable

Long Term Notes Payable at other companies

Ocular Therapeutix logo
Ocular TherapeutixOCUL

Other financials

Income statement

See full
Revenue$44.2M-7.6%
Gross profit$27.0M-16.3%
Operating income-$22.1M-96.6%
Net income-$27.6M-55.2%
EPS (diluted)-$0.74-48.0%

Balance sheet

See full
Cash & equivalents$94.6M+41.8%
Total debt$308.6M-32.9%
Total equity$28.7M-49.1%
Total assets$419.5M+15.2%

Cash flow

See full
Operating cash flow-$9.0M-146%
CapEx$194.0K+14.1%
Free cash flow-$9.2M-147%

Valuation

See full
Market cap$1.59B+38.4%

Profitability

See full
Gross margin74.1%-0.4pp
Operating margin7.3%+5.2pp
Net margin-19.8%+18.0pp
FCF margin5.7%+5.0pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity10.7×+2.6×
Current ratio2.5×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:LongTermNotesPayable.

The official record: Harrow’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harrow's long term notes payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harrow's long term notes payable?
Harrow (HROW) reported long term notes payable of $292.09M in Q1 2026.
How has Harrow's long term notes payable changed year-over-year?
Harrow's long term notes payable increased by 159.6% year-over-year, from $112.5M to $292.09M.
What is the long-term trend for Harrow's long term notes payable?
Over 5 years (2020 to 2025), Harrow's long term notes payable has grown at a 81.4% compound annual growth rate (CAGR), from $12.38M to $243.18M.